Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
The brokerage remains optimistic on Emcure's growth prospects and expects the company to deliver low- to mid-teen revenue growth in FY27. It also forecasts EBITDA margin expansion of 75-100 basis points during the year.
According to the brokerage, margin improvement is likely to be driven by higher productivity of the company's field force in India and new product launches across key international markets.
The brokerage highlighted Emcure's focus on research and development-backed products as a key pillar of its long-term growth strategy.
Reflecting its improved outlook, the brokerage raised its earnings per share (EPS) estimates by 1-5% and expects the company to deliver an EPS compound annual growth rate (CAGR) of around 20% over FY26-FY29.
Pune-based Emcure Pharmaceuticals develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally, including Europe and Canada.
On a consolidated basis, Emcure Pharmaceuticals' net profit rose 28.81% to Rs 243.40 crore while net sales rose 16.70% to Rs 2469.70 crore in Q4 March 2026 over Q4 March 2025.
360 ONE WAM Ltd, Emcure Pharmaceuticals Ltd, DLF Ltd, Niva Bupa Health Insurance Company Ltd are among the other stocks to see a surge in volumes on BSE today, 15 June 2026.
Balkrishna Industries Ltd witnessed volume of 6.96 lakh shares by 10:47 IST on BSE, a 60.02 times surge over two-week average daily volume of 11593 shares. The stock increased 3.82% to Rs.2,089.50. Volumes stood at 9649 shares in the last session.
360 ONE WAM Ltd saw volume of 3.13 lakh shares by 10:47 IST on BSE, a 16.47 fold spurt over two-week average daily volume of 18975 shares. The stock increased 3.12% to Rs.1,129.75. Volumes stood at 16219 shares in the last session.
Emcure Pharmaceuticals Ltd recorded volume of 2.04 lakh shares by 10:47 IST on BSE, a 16.13 times surge over two-week average daily volume of 12654 shares. The stock lost 0.96% to Rs.1,717.55. Volumes stood at 2813 shares in the last session.
DLF Ltd clocked volume of 5.92 lakh shares by 10:47 IST on BSE, a 7.64 times surge over two-week average daily volume of 77492 shares. The stock gained 3.00% to Rs.604.75. Volumes stood at 1.02 lakh shares in the last session.
Niva Bupa Health Insurance Company Ltd recorded volume of 40.88 lakh shares by 10:47 IST on BSE, a 7.41 times surge over two-week average daily volume of 5.51 lakh shares. The stock gained 0.78% to Rs.84.78. Volumes stood at 45865 shares in the last session.
For the full year,net profit rose 35.67% to Rs 924.36 crore in the year ended March 2026 as against Rs 681.33 crore during the previous year ended March 2025. Sales rose 16.56% to Rs 9203.54 crore in the year ended March 2026 as against Rs 7896.00 crore during the previous year ended March 2025.
Sapphire Foods India Ltd, Emcure Pharmaceuticals Ltd, Garden Reach Shipbuilders & Engineers Ltd and Great Eastern Shipping Company Ltd are among the other gainers in the BSE's 'A' group today, 29 April 2026.
Bandhan Bank Ltd surged 12.20% to Rs 200.05 at 11:47 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 31.09 lakh shares were traded on the counter so far as against the average daily volumes of 5.18 lakh shares in the past one month.
Sapphire Foods India Ltd spiked 9.78% to Rs 191.9. The stock was the second biggest gainer in 'A' group. On the BSE, 81961 shares were traded on the counter so far as against the average daily volumes of 98611 shares in the past one month.
Emcure Pharmaceuticals Ltd soared 8.69% to Rs 1749.05. The stock was the third biggest gainer in 'A' group. On the BSE, 45820 shares were traded on the counter so far as against the average daily volumes of 12020 shares in the past one month.
Garden Reach Shipbuilders & Engineers Ltd exploded 8.47% to Rs 3118.8. The stock was the fourth biggest gainer in 'A' group. On the BSE, 9.33 lakh shares were traded on the counter so far as against the average daily volumes of 1.89 lakh shares in the past one month.
Great Eastern Shipping Company Ltd rose 7.25% to Rs 1582. The stock was the fifth biggest gainer in 'A' group. On the BSE, 3.13 lakh shares were traded on the counter so far as against the average daily volumes of 26095 shares in the past one month.
Emcure Pharmaceuticals Ltd, Aster DM Healthcare Ltd, PG Electroplast Ltd, Happiest Minds Technologies Ltd are among the other stocks to see a surge in volumes on NSE today, 09 March 2026.
Sonata Software Ltd clocked volume of 54.99 lakh shares by 14:14 IST on NSE, a 7.98 times surge over two-week average daily volume of 6.89 lakh shares. The stock gained 0.61% to Rs.247.95. Volumes stood at 9.16 lakh shares in the last session.
Emcure Pharmaceuticals Ltd recorded volume of 15.92 lakh shares by 14:14 IST on NSE, a 6.96 times surge over two-week average daily volume of 2.29 lakh shares. The stock gained 7.50% to Rs.1,522.00. Volumes stood at 1.05 lakh shares in the last session.
Aster DM Healthcare Ltd registered volume of 28.41 lakh shares by 14:14 IST on NSE, a 4.42 fold spurt over two-week average daily volume of 6.43 lakh shares. The stock slipped 1.89% to Rs.660.00. Volumes stood at 14.34 lakh shares in the last session.
PG Electroplast Ltd recorded volume of 71.03 lakh shares by 14:14 IST on NSE, a 4.16 times surge over two-week average daily volume of 17.06 lakh shares. The stock lost 13.13% to Rs.529.25. Volumes stood at 13.29 lakh shares in the last session.
Happiest Minds Technologies Ltd saw volume of 18.99 lakh shares by 14:14 IST on NSE, a 4.03 fold spurt over two-week average daily volume of 4.71 lakh shares. The stock dropped 0.19% to Rs.336.85. Volumes stood at 3.24 lakh shares in the last session.
Emcure Pharmaceuticals announced the signing of a distribution agreement with Roche for select products in the nephrology and transplant medicine portfolio. The agreement marks a significant step toward expanding patient access to critical therapies in chronic kidney disease (CKD), anemia management, and transplant care across India. Under the agreement, which will be effective 01 April 2026, Emcure will distribute Roche's established and globally recognised brands in the nephrology and transplant segment in India.
The agreement includes the following brands:
Commenting on the agreement, Satish Mehta, Managing Director & CEO, Emcure Pharmaceuticals, said, “This partnership with Roche is a natural extension of Emcure's commitment to improving outcomes in anemia and renal care. Roche's globally trusted innovations strongly complement our existing portfolio and reach. Together, we aim to expand access to these critical therapies and support physicians in delivering op mal care to patients across India.”